Overview

A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC

Status:
Terminated

Trial end date:
2016-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).

Phase:

Phase 3

Details

Lead Sponsor:

Novus Therapeutics, Inc
Tokai Pharmaceuticals

Treatments:

3-hydroxy-17-(1H-benzimidazole-1-yl)androsta-5,16-diene
Androgens